IndustryCompany release

Glaukos third-quarter sales rise 58% to $211.0m as company raises 2026 guidance

🇺🇸 GLAUKOS Corp (GKOS) · Wed 28 Oct 2026

Glaukos reported record Q3 net sales driven by iDose TR and the newly approved Epioxa, lifted its 2026 outlook and set a preliminary $1bn target for 2027.

Glaukos Corporation reported record net sales of $211.0 million for the third quarter of 2026, a 58% increase on the same period a year earlier. The company announced the results on 28 October 2026.

The company attributed growth to iDose TR in glaucoma and to Epioxa, its corneal cross-linking therapy for keratoconus, which has FDA approval. U.S. Glaucoma sales reached $118.6 million, while Corneal Health sales totalled $59.0 million.

Glaukos posted net income of $2.0 million for the quarter. It raised its 2026 net sales guidance to a range of $775 million to $785 million.

Looking further ahead, the company gave preliminary 2027 guidance of $1 billion in net sales. The summary available does not include further detail on how the figures break down by product or region beyond those segments, nor on the assumptions behind the 2027 outlook.

What it means for your team

  • Market-access teams should note that iDose TR and Epioxa are reported as the main growth drivers, which suggests continued commercial uptake of both products in the U.S.
  • Epioxa is described as FDA-approved, so its Corneal Health sales reflect a therapy now on the U.S. market for keratoconus.
  • The $1 billion preliminary 2027 guidance is a company projection, not a result, and depends on assumptions not detailed in the available information.

Company's press release (SEC filing): GLAUKOS Corp ↗

Article written by VigiEye from the official source (GLAUKOS Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →